CRD-799 / Chordia Therap - LARVOL DELTA

Combining HRI/PERK/GCN2 inhibitor CRD-799 with proteasome inhibitors provides a novel approach to overcoming resistance in multiple myeloma treatment (AACR 2025) - "The introduction of novel treatments for multiple myeloma (MM), particularly proteasome inhibitors (PIs) such as bortezomib (BTZ), has significantly improved patient outcomes. In summary, the combination of the HRI/PERK/GCN2 inhibitor CRD-799 with PIs offers a promising strategy to overcome PI resistance in MM. These findings provide critical mechanistic insights into the heterogeneity of treatment responses, potentially guiding the personalized application of this combination therapy in clinical settings."

Hematological Malignancies • Multiple Myeloma • Oncology • ATF3 • ATF4 • ERN1 • MAPK8

Chordia presents new data at the American Association for Cancer Research Annual Meeting 2025 (Chordia Therapeutics Press Release) - "Chordia Therapeutics Inc...announces that Chordia presents new data of CDK12 inhibitor CTX-439 and GCN2 inhibitor at the American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025, in Chicago, Illinois....CTX-439 suppresses the production of MCL1, a protein critical for cancer cell survival, and exhibits marked antitumor activity when combined with a BCL2/BCL-xL inhibitor....CRD-799, in combination with existing proteasome inhibitors, demonstrated clear anti-tumor efficacy. In this combination therapy, CRD-799 controls the stress response pathway in cancer cells and induces cell death, which is the mechanism underlying its antitumor effects."

Preclinical • Multiple Myeloma

Presentation of data from our pipeline at the American Association for Cancer Research Annual Meeting 2025 (Chordia Therapeutics Press Release) - "Chordia Therapeutics Inc...announces that Chordia will present new data at the American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025, in Chicago, Illinois. Two presentations will be given on Chordia's pipeline of CDK12 inhibitor CTX-439, and a GCN2 inhibitor."

Preclinical • Multiple Myeloma